1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Piprot, C; Cals, L; Chaigneau, L; Demarchi, F; N'Guyen, T; Stein, U; Villanueva, C; Bréau, JL; Chouahnia, AK; Saintigny, P; Boué, F; deSaint-Hilaire, P; Guimont, I; Grossat, N; Valenza, B; Lévy, E; Médioni, J; Delbaldo, C; Grenier, J; Pouessel, D Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, Pierre; Serin, Daniel; Jacquin, Jean-Philippe; Jouannaud, Christelle; Rios, Maria; Abadie-Lacourtoisie, Sophie; Venat-Bouvet, Laurence; Cany, Laurent; Catal... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Issue 5 (May 2016) Authors: Bertucci, François; Fekih, Mahmoud; Autret, Aurélie; Petit, Thierry; Dalenc, Florence; Levy, Christelle; Romieu, Gilles; Bonneterre, Jacques; Ferrero, Jean-Marc; Kerbrat, Pierre; Soulie, Patrick; Mouret-Reynier, Marie-Ange; Bachelot, Thomas; Lerebours, Florence; Eymard, Jean-Christophe; Deblock, ... Journal: Lancet oncology Issue: Volume 17:Issue 5(2016:May) Page Start: 600 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cancer‐related fatigue in breast cancer patients after surgery: a multicomponent model using partial least squares—path modeling. Issue 4 (22nd October 2013) Authors: Bortolon, Catherine; Krikorian, Alicia; Carayol, Marion; Brouillet, Denis; Romieu, Gilles; Ninot, Gregory Journal: Psycho-oncology Issue: Volume 23:Issue 4(2014) Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Issue 13 (September 2015) Authors: Pivot, Xavier; Suter, Thomas; Nabholtz, Jean Marc; Pierga, Jean Yves; Espie, Marc; Lortholary, Alain; Khayat, David; Pauporte, Iris; Romieu, Gilles; Kramar, Andrew; Fumoleau, Pierre Journal: European journal of cancer Issue: Volume 51:Issue 13(2015:Sep.) Page Start: 1660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab. (October 2018) Authors: Jacquinot, Quentin; Paget-Bailly, Sophie; Fumoleau, Pierre; Romieu, Gilles; Pierga, Jean Yves; Espié, Marc; Lortholary, Alain; Nabholtz, Jean Marc; Mercier, Celine Faure; Pauporté, Iris; Henriques, Julie; Pivot, Xavier Journal: Breast Issue: Volume 41(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. HER2 overexpression a major risk factor for recurrence in pT1a‐bN0M0 breast cancer: results from a French regional cohort. (10th January 2014) Authors: Rouanet, Philippe; Roger, Pascal; Rousseau, Emilie; Thibault, Severine; Romieu, Gilles; Mathieu, Andre; Cretin, Jacques; Barneon, Gilbert; Granier, Mireille; Maran‐Gonzalez, Aurelie; Daures, Jean P.; Boissiere, Florence; Bibeau, Frederic Journal: Cancer medicine Issue: Volume 3:Number 1(2014:Feb.) Page Start: 134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. HER2 overexpression a major risk factor for recurrence in pT1a‐bN0M0 breast cancer: results from a French regional cohort. (10th January 2014) Authors: Rouanet, Philippe; Roger, Pascal; Rousseau, Emilie; Thibault, Severine; Romieu, Gilles; Mathieu, Andre; Cretin, Jacques; Barneon, Gilbert; Granier, Mireille; Maran‐Gonzalez, Aurelie; Daures, Jean P.; Boissiere, Florence; Bibeau, Frederic Journal: Cancer medicine Issue: Volume 3:Number 1(2014:Feb.) Page Start: 134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. Issue 1 (December 2015) Authors: Jacot, William; Mollevi, Caroline; Fina, Frédéric; Lopez-Crapez, Evelyne; Martin, Pierre-Marie; Colombo, Pierre-Emmanuel; Bibeau, Frédéric; Romieu, Gilles; Lamy, Pierre-Jean Journal: BMC cancer Issue: Volume 15:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer. (February 2014) Authors: Saadoun, Haïdar; Lamy, Pierre-Jean; Thezenas, Simon; Pouderoux, Stéphane; Bibeau, Frédéric; Montels, Frédéric; Romieu, Gilles; Colombo, Pierre-Emmanuel; Gutowski, Marian; Jacot, William Journal: Future oncology Issue: Volume 10:Number 2(2014) Page Start: 195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗